1
|
Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen. Cancers (Basel) 2020; 12:cancers12051123. [PMID: 32365878 PMCID: PMC7281530 DOI: 10.3390/cancers12051123] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 04/15/2020] [Accepted: 04/21/2020] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Breast cancer (BC) is a heterogeneous disease for which the commonly used chemotherapeutic agents primarily include the anthracyclines (doxorubicin, epirubicin), microtubule inhibitors (paclitaxel, docetaxel, eribulin), and alkylating agents (cyclophosphamide). While these drugs can be highly effective, metastatic tumours are frequently refractory to treatment or become resistant upon tumour relapse. METHODS We undertook a cell polarity/epithelial mesenchymal plasticity (EMP)-enriched short hairpin RNA (shRNA) screen in MDA-MB-468 breast cancer cells to identify factors underpinning heterogeneous responses to three chemotherapeutic agents used clinically in breast cancer: Doxorubicin, docetaxel, and eribulin. shRNA-transduced cells were treated for 6 weeks with the EC10 of each drug, and shRNA representation assessed by deep sequencing. We first identified candidate genes with depleted shRNA, implying that their silencing could promote a response. Using the Broad Institute's Connectivity Map (CMap), we identified partner inhibitors targeting the identified gene families that may induce cell death in combination with doxorubicin, and tested them with all three drug treatments. RESULTS In total, 259 shRNAs were depleted with doxorubicin treatment (at p < 0.01), 66 with docetaxel, and 25 with eribulin. Twenty-four depleted hairpins overlapped between doxorubicin and docetaxel, and shRNAs for TGFB2, RUNX1, CCDC80, and HYOU1 were depleted across all the three drug treatments. Inhibitors of MDM/TP53, TGFBR, and FGFR were identified by CMap as the top pharmaceutical perturbagens and we validated the combinatorial benefits of the TGFBR inhibitor (SB525334) and MDM inhibitor (RITA) with doxorubicin treatment, and also observed synergy between the inhibitor SB525334 and eribulin in MDA-MB-468 cells. CONCLUSIONS Taken together, a cell polarity/EMP-enriched shRNA library screen identified relevant gene products that could be targeted alongside current chemotherapeutic agents for the treatment of invasive BC.
Collapse
|
2
|
RITA induces apoptosis in p53-null K562 leukemia cells by inhibiting STAT5, Akt, and NF-κB signaling pathways. Anticancer Drugs 2019; 29:847-853. [PMID: 30157040 DOI: 10.1097/cad.0000000000000651] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Targeting oncogenic signaling pathways by small molecules has emerged as a potential treatment strategy for cancer. reactivation of p53 and induction of tumor cell apoptosis (RITA) is a promising anticancer small molecule that reactivates p53 and induces exclusive apoptosis in tumor cells. Less well appreciated was the possible effect of small molecule RITA on p53-null leukemia cells. In this study, we demonstrated that RITA has potent antileukemic properties against p53-null chronic myeloid leukemia (CML)-derived K562 cells. RITA triggered apoptosis through caspase-9 and caspase-3 activation and poly (ADP-ribose) polymerase cleavage. RITA decreased STAT5 tyrosine phosphorylation, although it did not inhibit phosphorylation of the direct BCR-ABL substrate CrkL. Real-time PCR analysis showed that RITA downregulates antiapoptotic STAT5 target genes Bcl-xL and MCL-1. The downregulation of nuclear factor-κB (NF-κB), as evidenced by inhibition of IκB-α phosphorylation and its degradation, was associated with inhibition of Akt phosphorylation in RITA-treated cells. Furthermore, consistent with the decrease of mRNA levels, protein levels of the nuclear factor-κB-regulated antiapoptotic (cIAP1, XIAP, and Bcl-2) and proliferative (c-Myc) genes were downregulated by RITA in K562 cells. In conclusion, the ability of RITA to inhibit prosurvival signaling pathways in CML cells suggests a potential application of RITA in CML therapeutic protocols.
Collapse
|
3
|
Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, Schulte JH, Künkele A. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. Oncotarget 2017; 8:27882-27891. [PMID: 28427187 PMCID: PMC5438615 DOI: 10.18632/oncotarget.15840] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Accepted: 02/20/2017] [Indexed: 01/08/2023] Open
Abstract
Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40-70% survival. Secondary chemotherapy resistance contributes to treatment failure, where TP53 pathway dysfunction plays a key role. MDM2 interaction with TP53 leads to its degradation. Reactivating TP53 functionality using small-molecule inhibitors, such as RITA, to disrupt TP53-MDM2 binding may have therapeutic potential. We show here that RITA decreased viability of all 4 analyzed medulloblastoma cell lines, regardless of TP53 functional status. The decrease in cell viability was accompanied in 3 of the 4 medulloblastoma cell lines by accumulation of TP53 protein in the cells and increased CDKN1A expression. RITA treatment in mouse models inhibited medulloblastoma xenograft tumor growth. These data demonstrate that RITA treatment reduces medulloblastoma cell viability in both in vitro and in vivo models, and acts independently of cellular TP53 status, identifying RITA as a potential therapeutic agent to treat medulloblastoma.
Collapse
Affiliation(s)
- Aline Gottlieb
- Department of Pediatric Oncology, University Hospital Essen, 45122 Essen, Germany
| | - Kristina Althoff
- Department of Pediatric Oncology, University Hospital Essen, 45122 Essen, Germany
| | - Laura Grunewald
- Department of Pediatric Oncology, Hematology and SCT, Charité, 13353 Berlin, Germany
| | - Theresa Thor
- Department of Pediatric Oncology, University Hospital Essen, 45122 Essen, Germany
| | - Andrea Odersky
- Department of Pediatric Oncology, University Hospital Essen, 45122 Essen, Germany
| | - Marc Schulte
- Department of Pediatric Oncology, University Hospital Essen, 45122 Essen, Germany
| | - Hedwig E. Deubzer
- Department of Pediatric Oncology, Hematology and SCT, Charité, 13353 Berlin, Germany
- Junior Neuroblastoma Research Group, Experimental and Clinical Research Center of the Max-Delbrück Center for Molecular Medicine (MDC), 13125 Berlin, Germany
| | - Lukas Heukamp
- Institute for Pathology, University Hospital of Cologne, 50924 Cologne, Germany
| | - Angelika Eggert
- Department of Pediatric Oncology, Hematology and SCT, Charité, 13353 Berlin, Germany
- German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- Berlin Institute of Health (BIH), 10117 Berlin, Germany
| | - Alexander Schramm
- Department of Pediatric Oncology, University Hospital Essen, 45122 Essen, Germany
| | - Johannes H. Schulte
- Department of Pediatric Oncology, Hematology and SCT, Charité, 13353 Berlin, Germany
- German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Annette Künkele
- Department of Pediatric Oncology, Hematology and SCT, Charité, 13353 Berlin, Germany
- Berlin Institute of Health (BIH), 10117 Berlin, Germany
| |
Collapse
|
4
|
Luo ZY, Jiang H, Xu L, Zhang XH. [Rita induce acute lymphoblostic leukemia cell apoptosis by activating P53 pathway]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2017; 38:160-163. [PMID: 28279043 PMCID: PMC7354173 DOI: 10.3760/cma.j.issn.0253-2727.2017.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | - H Jiang
- Department of Hematology, Guangzhou Women and Children Medical Center, Guangzhou Medical University, Guangzhou 510623, China
| | | | | |
Collapse
|
5
|
Peterson LF, Lo MC, Liu Y, Giannola D, Mitrikeska E, Donato NJ, Johnson CN, Wang S, Mercer J, Talpaz M. Induction of p53 suppresses chronic myeloid leukemia. Leuk Lymphoma 2017; 58:1-14. [PMID: 28084835 DOI: 10.1080/10428194.2016.1272682] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Chronic myeloid leukemia (CML) is characterized by the chromosomal translocation 9;22, known as the Philadelphia chromosome (Ph), which produces the BCR-ABL fusion tyrosine kinase. Although well-managed by BCR-ABL tyrosine kinase inhibitors (TKIs), treatment fails to eliminate Ph + primitive progenitors, and cessation of therapy frequently results in relapse. The p53 protein is an important regulator of cell cycle and apoptosis. The small molecules MI-219 target the interaction between p53 and its negative regulator HDM2, leading to its stabilization and activation. We show that treatment with MI-219 reduced the number of CML cells in both in vitro and in vivo settings but not that of normal primitive progenitors, and activated different gene signatures in CML potentially explaining the differential impact of this agent on each population. Our data suggest that a p53-activating agent may be an effective approach in the management and potential operational cure of CML.
Collapse
Affiliation(s)
- Luke F Peterson
- a Comprehensive Cancer Center , University of Michigan , Ann Arbor , MI , USA.,b Department of Internal Medicine, Division of Hematology and Oncology , University of Michigan , Ann Arbor , MI , USA
| | - Miao-Chia Lo
- c College of Pharmacy, University of Michigan , Ann Arbor , MI , USA
| | - Yihong Liu
- a Comprehensive Cancer Center , University of Michigan , Ann Arbor , MI , USA.,b Department of Internal Medicine, Division of Hematology and Oncology , University of Michigan , Ann Arbor , MI , USA
| | - Diane Giannola
- a Comprehensive Cancer Center , University of Michigan , Ann Arbor , MI , USA
| | - Emilija Mitrikeska
- a Comprehensive Cancer Center , University of Michigan , Ann Arbor , MI , USA.,b Department of Internal Medicine, Division of Hematology and Oncology , University of Michigan , Ann Arbor , MI , USA
| | - Nicholas J Donato
- a Comprehensive Cancer Center , University of Michigan , Ann Arbor , MI , USA.,b Department of Internal Medicine, Division of Hematology and Oncology , University of Michigan , Ann Arbor , MI , USA
| | - Craig N Johnson
- d DNA Sequencing and Microarray Core , University of Michigan , Ann Arbor , MI , USA
| | - Shaomeng Wang
- e Department of Pharmacology and Medicinal Chemistry , University of Michigan , Ann Arbor , MI , USA
| | - Jessica Mercer
- a Comprehensive Cancer Center , University of Michigan , Ann Arbor , MI , USA.,b Department of Internal Medicine, Division of Hematology and Oncology , University of Michigan , Ann Arbor , MI , USA
| | - Moshe Talpaz
- a Comprehensive Cancer Center , University of Michigan , Ann Arbor , MI , USA.,b Department of Internal Medicine, Division of Hematology and Oncology , University of Michigan , Ann Arbor , MI , USA
| |
Collapse
|
6
|
Koltan S, Debski R, Koltan A, Grzesk E, Tejza B, Eljaszewicz A, Gackowska L, Kubicka M, Kolodziej B, Kurylo-Rafinska B, Kubiszewska I, Wiese M, Januszewska M, Michalkiewicz J, Wysocki M, Styczynski J, Grzesk G. Phenotype of NK Cells Determined on the Basis of Selected Immunological Parameters in Children Treated due to Acute Lymphoblastic Leukemia. Medicine (Baltimore) 2015; 94:e2369. [PMID: 26717380 PMCID: PMC5291621 DOI: 10.1097/md.0000000000002369] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Acute lymphoblastic leukemia (ALL) is the most frequent pediatric malignancy. The chemotherapy for ALL is associated with a profound secondary immune deficiency.We evaluated the number and phenotype of natural killer (NK) cells at diagnosis, after the intensive chemotherapy and following the completion of the entire treatment for patients with ALL. The fraction, absolute number, and percentage of NK cells expressing interferon-γ were determined in full blood samples. The fraction of NK cells expressing CD158a, CD158b, perforin, A, B, and K granzymes was examined in isolated NK cells.We have shown that patients assessed at ALL diagnosis showed significantly lower values of the fraction of NK cells and percentage of NK cells with the granzyme A expression. Additionally, the absolute number of NK cells, the expression of CD158a, CD158b, perforin, and granzyme A were significantly lower in patients who completed intensive chemotherapy. Also, there was a significantly higher fraction of NK cells expressing granzyme K in patients who completed the therapy.Abnormalities of NK cells were found at all stages of the treatment; however, the most pronounced changes were found at the end of intensive chemotherapy.
Collapse
Affiliation(s)
- Sylwia Koltan
- From the Departments of Pediatrics, Hematology and Oncology; and Immunology (SK, RD, AK, EG, BT, AE, LG, MK, BK, BK-R, IK, M Wiese, MJ, JM, M Wysocki, JS), Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, and Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland (GG)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Mantovani F, Zannini A, Rustighi A, Del Sal G. Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships. Biochim Biophys Acta Gen Subj 2015; 1850:2048-60. [PMID: 25641576 DOI: 10.1016/j.bbagen.2015.01.013] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2014] [Revised: 01/17/2015] [Accepted: 01/19/2015] [Indexed: 01/11/2023]
Abstract
BACKGROUND The p53 protein family, comprising p53, p63 and p73, is primarily involved in preserving genome integrity and preventing tumor onset, and also affects a range of physiological processes. Signal-dependent modifications of its members and of other pathway components provide cells with a sophisticated code to transduce a variety of stress signaling into appropriate responses. TP53 mutations are highly frequent in cancer and lead to the expression of mutant p53 proteins that are endowed with oncogenic activities and sensitive to stress signaling. SCOPE OF REVIEW p53 family proteins have unique structural and functional plasticity, and here we discuss the relevance of prolyl-isomerization to actively shape these features. MAJOR CONCLUSIONS The anti-proliferative functions of the p53 family are carefully activated upon severe stress and this involves the interaction with prolyl-isomerases. In particular, stress-induced stabilization of p53, activation of its transcriptional control over arrest- and cell death-related target genes and of its mitochondrial apoptotic function, as well as certain p63 and p73 functions, all require phosphorylation of specific S/T-P motifs and their subsequent isomerization by the prolyl-isomerase Pin1. While these functions of p53 counteract tumorigenesis, under some circumstances their activation by prolyl-isomerases may have negative repercussions (e.g. tissue damage induced by anticancer therapies and ischemia-reperfusion, neurodegeneration). Moreover, elevated Pin1 levels in tumor cells may transduce deregulated phosphorylation signaling into activation of mutant p53 oncogenic functions. GENERAL SIGNIFICANCE The complex repertoire of biological outcomes induced by p53 finds mechanistic explanations, at least in part, in the association between prolyl-isomerases and the p53 pathway. This article is part of a Special Issue entitled Proline-directed foldases: Cell signaling catalysts and drug targets.
Collapse
Affiliation(s)
- Fiamma Mantovani
- Laboratorio Nazionale CIB (LNCIB), Area Science Park, Trieste, Italy; Dipartimento di Scienze della Vita, Università degli Studi di Trieste, Trieste, Italy
| | - Alessandro Zannini
- Laboratorio Nazionale CIB (LNCIB), Area Science Park, Trieste, Italy; Dipartimento di Scienze della Vita, Università degli Studi di Trieste, Trieste, Italy
| | - Alessandra Rustighi
- Laboratorio Nazionale CIB (LNCIB), Area Science Park, Trieste, Italy; Dipartimento di Scienze della Vita, Università degli Studi di Trieste, Trieste, Italy
| | - Giannino Del Sal
- Laboratorio Nazionale CIB (LNCIB), Area Science Park, Trieste, Italy; Dipartimento di Scienze della Vita, Università degli Studi di Trieste, Trieste, Italy.
| |
Collapse
|
8
|
Safa M, Tavasoli B, Manafi R, Kiani F, Kashiri M, Ebrahimi S, Kazemi A. Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells. Tumour Biol 2015; 36:3919-30. [DOI: 10.1007/s13277-014-3035-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2014] [Accepted: 12/30/2014] [Indexed: 01/07/2023] Open
|
9
|
Abstract
This article summarizes data on translational studies to target the p53 pathway in cancer. It describes the functions of the p53 and Mdm-2 signaling pathways, and discusses current therapeutic approaches to target p53 pathways, including reactivation of p53. In addition, direct interaction and colocalization of the p53 and focal adhesion kinase proteins in cancer cells have been demonstrated, and different approaches to target this interaction are reviewed. This is a broad review of p53 function as it relates to the diagnosis and treatment of a wide range of cancers.
Collapse
|
10
|
Saha MN, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 2013; 6:23. [PMID: 23531342 PMCID: PMC3614876 DOI: 10.1186/1756-8722-6-23] [Citation(s) in RCA: 93] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Accepted: 03/13/2013] [Indexed: 12/11/2022] Open
Abstract
p53 is a powerful tumor suppressor and is an attractive cancer therapeutic target. A breakthrough in cancer research came from the discovery of the drugs which are capable of reactivating p53 function. Most anti-cancer agents, from traditional chemo- and radiation therapies to more recently developed non-peptide small molecules exert their effects by enhancing the anti-proliferative activities of p53. Small molecules such as nutlin, RITA, and PRIMA-1 that can activate p53 have shown their anti-tumor effects in different types of hematological malignancies. Importantly, nutlin and PRIMA-1 have successfully reached the stage of phase I/II clinical trials in at least one type of hematological cancer. Thus, the pharmacological activation of p53 by these small molecules has a major clinical impact on prognostic use and targeted drug design. In the current review, we present the recent achievements in p53 research using small molecules in hematological malignancies. Anticancer activity of different classes of compounds targeting the p53 signaling pathway and their mechanism of action are discussed. In addition, we discuss how p53 tumor suppressor protein holds promise as a drug target for recent and future novel therapies in these diseases.
Collapse
Affiliation(s)
- Manujendra N Saha
- Division of Molecular and Cellular Biology, Toronto General Research Institute, Toronto, Canada
| | | | | |
Collapse
|
11
|
Abstract
In response to intense stress, the tumor protein p53 (p53) tumor suppressor rapidly
mounts a direct mitochondrial death program that precedes transcription-mediated
apoptosis. By eliminating severely damaged cells, this pathway contributes to tumor
suppression as well as to cancer cell killing induced by both genotoxic drugs and
non-genotoxic p53-reactivating molecules. Here we have explored the role had in this
pathway by the prolyl-isomerase Pin1 (peptidylprolyl cis/trans isomerase,
NIMA-interacting 1), a crucial transducer of p53's phosphorylation into
conformational changes unleashing its pro-apoptotic activity. We show that Pin1 promotes
stress-induced localization of p53 to mitochondria both in vitro and in
vivo. In particular, we demonstrate that upon stress-induced phosphorylation of p53
on Ser46 by homeodomain interacting protein kinase 2, Pin1 stimulates its mitochondrial
trafficking signal, that is, monoubiquitination. This pathway is induced also by the
p53-activating molecule RITA, and we demonstrate the strong requirement of Pin1 for the
induction of mitochondrial apoptosis by this compound. These findings have significant
implications for treatment of p53-expressing tumors and for prospective use of
p53-activating compounds in clinics.
Collapse
|